



## Authors' Reply: Relevance of Level I Ib Neck Dissection in Patients with Head and Neck Squamous Cell Carcinomas

Seiji Hosokawa<sup>1</sup> · Daiki Mochizuki<sup>1</sup> · Goro Takahashi<sup>1,2</sup> · Jun Okamura<sup>1,3</sup> · Atsushi Imai<sup>1</sup> · Ryuji Ishikawa<sup>1</sup> · Yoshinori Takizawa<sup>1</sup> · Takashi Yamatodani<sup>1</sup> · Kiyoshi Misawa<sup>1</sup> · Hiroyuki Mineta<sup>1</sup>

Published online: 2 March 2020  
© Société Internationale de Chirurgie 2020

Dear Editor,

We thank Dr. Abhinav Thaduri and colleagues for their valuable comments on our paper titled “Relevance of level I Ib neck dissection in patients with head and neck squamous cell carcinomas” [1]. We agree that the retrospective design of our study represented a major limitation because it resulted in certain inconsistencies, and that the study population was heterogeneous and predominantly included hypopharyngeal and oropharyngeal cancers. Accordingly, we need to exercise caution while generalizing the applicability of I Ib neck dissection to all subsets of head and neck squamous cell cancers, considering that different subsets exhibit different lymphatic drainage patterns.

The aim of our study was to develop an alternative diagnostic tool and a therapeutic procedure that can identify the factors contributing to preservation of the function and performance of the spinal accessory nerve. Indeed, our study did not address the oncological (locoregional failure) and survival outcomes. In cases of therapeutic neck dissection, there is a strong association between the positivity of level I Ia metastasis and level I Ib involvement [2, 3]; therefore, we recommend the use of level I Ib dissection if level I Ia shows clinical node positivity.

As pointed out by Dr. Thaduri, a randomized controlled trial (RCT) by Wang et al. [4] seems to clarify issues

related to the oncological and functional safety of level I Ib neck node preservation. However, it should be noted that this RCT only included early stage cancers. Further prospective, controlled studies with advanced-stage samples are warranted to determine the correlation between clinically determined and pathologically confirmed level I Ib positivity.

Sincerely,  
Hosokawa S

**Funding** None.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

### References

1. Hosokawa S, Mochizuki D, Takahashi G et al (2019) Relevance of level I Ib neck dissection in patients with head and neck squamous cell carcinomas. *World J Surg* 43:3059–3064. <https://doi.org/10.1007/s00268-019-05147-z>
2. Corlette TH, Cole IE, Albsoul N et al (2005) Neck dissection of level I Ib: is it really necessary? *Laryngoscope* 115:1624–1626
3. Lim YC, Lee JS, Koo BS et al (2006) Level I Ib lymph node metastasis in laryngeal squamous cell carcinoma. *Laryngoscope* 116:268–272
4. Wang L, Wang L, Song X et al (2019) The necessity of I Ib dissection in T1–T2N0M0 oral squamous cell carcinoma: protocol for a randomized controlled trial. *Trials* 20:600

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

✉ Seiji Hosokawa  
sejih@hama-med.ac.jp

<sup>1</sup> Department of Otorhinolaryngology/Head and Neck Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan

<sup>2</sup> Yamahoshi ENT Clinic, Hamamatsu, Japan

<sup>3</sup> Department of Otorhinolaryngology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan